IP Library Granted Patent US 8,642,558
Granted Patent B2
US 8,642,558 · App. 13/119,675 · Granted Feb 4, 2014

Methods, systems, and compositions for calpain inhabition

Inventors: John Anagli (Walled Lake, MI); Donald Seyfried (Plymouth, MI)
Assignee: Henry Ford Health Systems
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,642,558
App. No.
13/119,675
Granted
Feb 4, 2014
Kind
B2
Abstract

Methods, systems and compositions comprising novel peptidomimetics are disclosed that can be used to inhibit calpain and, more specifically, to treat tissue damage caused by pathologic activation of calpains.

Claims (32)

1. A synthetic peptide comprising SEQ ID NO: 5.

2. A composition comprising:

the peptide of claim 1 ; and

an additive selected from the group consisting of a hydrophobic blood-brain-barrier or a membrane-permeant amino acid sequence linked by a polyethylene glycol linker to the N-terminus of said peptide, SEQ ID NO. 11, SEQ ID NO. 12, a nonaqueous vehicle, a solvent, a diluent, adjuvant, a chelating agent, a stability enhancing additive, antimicrobial preservatives, antioxidants, buffers, an antibacterial or an antifungal agents, parabens, chlorobutanol, phenol, sorbic acid, an isotonic agent, a sugar, sodium chloride, a prolonged absorption agent, aluminum monostearate, a gelatin and combinations thereof.

3. A method of inhibiting neuronal damage in a subject following an ischemic event, comprising the steps of:

providing the composition of claim 2 , and

administering a pharmaceutically effective amount of said composition to the subject.

4. A drug for inhibiting neural damage in a subject following an ischemic event, the drug comprising:

the peptide of claim 1 ; and

a pharmaceutically acceptable excipient or other additive selected from the group consisting of a hydrophobic blood-brain-barrier or a membrane-permeant amino acid sequence linked by a polyethylene glycol linker to the N-terminus of said peptide, SEQ ID NO. 11, SEQ ID NO. 12, a nonaqueous vehicle, a solvent, a diluent, adjuvant, a chelating agent, a stability enhancing additive, antimicrobial preservatives, antioxidants, buffers, an antibacterial or an antifungal agents, parabens, chlorobutanol, phenol, sorbic acid, an isotonic agent, a sugar, sodium chloride, a prolonged absorption agent, aluminum monostearate, a gelatin and combinations thereof.

5. A composition comprising:

one or more peptides of SEQ ID NOS: 3, 5, 6, 7, 8, 9, and 10.; and

a pharmaceutically acceptable excipient or other additive selected from the group consisting of a hydrophobic blood-brain-barrier or a membrane-permeant amino acid sequence linked by a polyethylene glycol linker to the N-terminus of said peptide, SEQ ID NO. 11, SEQ ID NO. 12, a nonaqueous vehicle, a solvent, a diluent, a chelating agent, a stability enhancing additive, antimicrobial preservatives, antioxidants, buffers, an antibacterial or an antifungal agents, parabens, chlorobutanol, phenol, sorbic acid, an isotonic agent, a sugar, sodium chloride, a prolonged absorption agent, aluminum monostearate, a gelatin and combinations thereof.

6. A method of inhibiting neuronal damage in a subject following an ischemic event, comprising the steps of:

providing the composition of claim 5 , and

administering a pharmaceutically effective amount of said composition to the subject.

7. A drug for inhibiting neural damage in a subject following an ischemic event, the drug comprising:

one or more peptide of SEQ ID NOS: 3, 5, 6, 7, 8, 9, or 10; and

a pharmaceutically acceptable excipient or other additive selected from the group consisting of a hydrophobic blood-brain-barrier or a membrane-permeant amino acid sequence linked by a polyethylene glycol linker to the N-terminus of said peptide, SEQ ID NO. 11, SEQ ID NO. 12, a nonaqueous vehicle, a solvent, a diluent, a chelating agent, a stability enhancing additive, antimicrobial preservatives, antioxidants, buffers, an antibacterial or an antifungal agents, parabens, chlorobutanol, phenol, sorbic acid, an isotonic agent, a sugar, sodium chloride, a prolonged absorption agent, aluminum monostearate, a gelatin and combinations thereof.

8. A synthetic peptide comprising SEQ ID NO: 2 or SEQ ID NO: 5 wherein the peptidic bond(s) of one or more of the following amino acid pairs in the sequence is replaced with a non-peptidic reduced amide bond: Ser4-Ser5, Tyr6-Ile7, Lys13-Arg14, Glu15-Val16, Lys21-Tyr22, Tyr22-Arg23.

9. A method of inhibiting neuronal damage in a subject following an ischemic event, comprising the steps of:

providing a composition comprised of the synthetic peptide of claim 8 , and administering a pharmaceutically effective amount of said composition to the subject.

10. A drug for inhibiting neural damage in a subject following an ischemic event, the drug comprising:

the synthetic peptide of claim 8 ; and

a pharmaceutically acceptable excipient or other additive selected from the group consisting of a hydrophobic blood-brain-barrier or a membrane-permeant amino acid sequence linked by a polyethylene glycol linker to the N-terminus of said peptide, SEQ ID NO. 11, SEQ ID NO. 12, a nonaqueous vehicle, a solvent, a diluent, a chelating agent, a stability enhancing additive, antimicrobial preservatives, antioxidants, buffers, an antibacterial or an antifungal agents, parabens, chlorobutanol, phenol, sorbic acid, an isotonic agent, a sugar, sodium chloride, a prolonged absorption agent, aluminum monostearate, a gelatin and combinations thereof.

11. A synthetic peptide comprising SEQ ID NO: 2, wherein there is side-chain cyclization between Lys21 and Glu24.

12. A method of inhibiting neuronal damage in a subject following an ischemic event, comprising the steps of:

providing a composition comprised of the synthetic peptide of claim 11 , and

administering a pharmaceutically effective amount of said composition to the mammal.

13. A drug for inhibiting neural damage in a subject following an ischemic event, the drug comprising:

the synthetic peptide of claim 11 ; and

a pharmaceutically acceptable excipient or other additive selected from the group consisting of a hydrophobic blood-brain-barrier or a membrane-permeant amino acid sequence linked by a polyethylene glycol linker to the N-terminus of said peptide, SEQ ID NO. 11, SEQ ID NO. 12, a nonaqueous vehicle, a solvent, a diluent, a chelating agent, a stability enhancing additive, antimicrobial preservatives, antioxidants, buffers, an antibacterial or an antifungal agents, parabens, chlorobutanol, phenol, sorbic acid, an isotonic agent, a sugar, sodium chloride, a prolonged absorption agent, aluminum monostearate, a gelatin and combinations thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2014
From: ANAGLI, JOHN; SEYFRIED, DONALD
To: HENRY FORD HEALTH SYSTEMS
Reel/Frame 032137/0628 →
Continuity (2)
Provisional Application 61098592 · Sep 19, 2008
Related Publication 20120028904A1 · Feb 2, 2012